MICS + trabeculectomy a good match

Article

Microincision cataract surgery (MICS) combined with trabeculectomy provides a one-year intraocular pressure (IOP) control comparable to that found with trabeculectomy and separate temporal clear corneal phaco, according to the results of a study by Dr Bayer and colleagues from the Ankara School of Medicine, Turkey.

Microincision cataract surgery (MICS) combined with trabeculectomy provides a one-year intraocular pressure (IOP) control comparable to that found with trabeculectomy and separate temporal clear corneal phaco, according to the results of a study by Dr Bayer and colleagues from the Ankara School of Medicine, Turkey.

A total of 63 eyes with co-existing cataract and glaucoma were randomly assigned to receive mitomycin-C (MMC) trabeculectomy in the superior quadrant combined with phaco and foldable intraocular lens (IOL) implantation through a separate, temporal, clear corneal incision (2-site group) or MMC trabeculectomy in a superior quadrant combined with MICS followed by IOL implantation from the trabeculectomy incision.

Mean preoperative IOP was 28.1±7.1 mmHg and 27.7±6.5 mmHg in the 2-site and MICS groups, respectively. At six-months postoperatively, mean IOP was 14.9±4.3 and 14.3±3.8 mmHg, respectively (p=0.7) and at 12 months, 15.6±3.3 and 15.1±3.1 mmHg, respectively (p=0.5). Postoperative astigmatic change and complications were comparable between the groups.

Dr Bayer concluded that MICS with trabeculectomy and trabeculectomy with separate temporal clear corneal phaco provide comparable IOP control at one-year.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.